The future of DNA patents
By Lisa A Haile
The US Supreme Court has ruled that certain patent claims owned by Myriad Genetics, the US biotech company that holds the patents covering a test for breast cancer-related genes (BRCA1 and BRCA2), are invalid as products of nature.
The implications for this decision, handed down on 13 June, may not be as far reaching in the biopharma industry as some have speculated. The decision is not likely to deter the innovation that is driving critical discoveries and therapies in the sector. In a decision that leaves some important questions unanswered, the Court both took away and left certain subject matter intact as patent eligible.
Full genes as excised from the genome, including coding and non-coding regions as they ‘occur naturally’, are no longer patentable. However, genes that have been manipulated in the lab (e.g, cDNA) are patentable and valid…
If you are registered and logged in to the site, click on the link below to read the rest of the DLA Piper briefing. If not, please register or sign in with your details below.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
China’s eagerly anticipated amendments to its Trademark Law will come into force on 1 May 2014
Tougher product liability provisions following the release of long-awaited amendments to consumer rights and interests protection law in China
The rise of consumerism in China over the past 10 years has spurred greater regulatory enforcement in the area of product liability.
Analysis from The Lawyer
The Lawyer’s latest Top 50 litigation firms list shows that business for dispute specialists is roaring along while new in-depth detail reveals the winning strategies
Our list of the summer’s big deals shows how London law firms kept busy with work from Asia as well as more familiar sources